title: Introduction: the dual-action debate: does pharmacology matter?
authors.affiliation: Department of Psychiatry, University of Pittsburgh Medical Center, 3811 O'Hara St., Pittsburgh, PA 15213-2593, USA. thaseme@upmc.edu
authors.forename: Michael E
authors.initials: ME
authors.lastname: Thase
mesh_terms: D000928:Antidepressive Agents / Q000494:pharmacology* / Q000627:therapeutic use*; D018687:Antidepressive Agents, Second-Generation / Q000494:pharmacology / Q000627:therapeutic use; D003865:Major Depressive Disorder / Q000188:drug therapy* / Q000503:physiopathology; D006801:Humans; D009638:Norepinephrine / Q000502:physiology; D012701:Serotonin / Q000502:physiology; D017367:Selective Serotonin Reuptake Inhibitors / Q000494:pharmacology / Q000627:therapeutic use; D016896:Treatment Outcome
chemical_list: D000928:Antidepressive Agents; D018687:Antidepressive Agents, Second-Generation; D009638:Norepinephrine; D012701:Serotonin; D017367:Selective Serotonin Reuptake Inhibitors